Dramatic response to neoadjuvant savolitinib in marginally resectable lung adenocarcinoma with MET exon 14 skipping mutation: A case report and literature review

Mesenchymal–epithelial transition (MET) exon 14 skipping mutation (METex14) is a low-frequency driver mutation in metastatic non-small cell lung cancer (NSCLC) (3%–4%) and is associated with a poor prognosis. With the advent of selective MET inhibitors such as capmatinib, tepotinib, and savolitinib,...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Jiangfang, Lin, Zhen, Chen, Yueyun, Fu, Yang, Ding, Zhenyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646987/
https://www.ncbi.nlm.nih.gov/pubmed/36387081
http://dx.doi.org/10.3389/fonc.2022.1006634

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646987/
https://www.ncbi.nlm.nih.gov/pubmed/36387081
http://dx.doi.org/10.3389/fonc.2022.1006634

Ejemplares similares